PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy
Go online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel therapies. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.